We showed that a negative regulator of β-catenin transcriptional activity, FZD6 (frizzled class receptor 6), is one of the key regulators related to luteolin treatment; it inhibits Wnt signaling pathway and the stemness of prostate cancer cells. Here, FZD6 is linked to Familial prostate cancer.